Eisai Co. Ltd announced that the company will present the latest findings on its Alzheimer’s disease pipeline and research, including Eisai’s anti-amyloid beta protofibril* antibody for the treatment of Alzheimer’s disease, lecanemab, and the company’s investigational anti-MTBR** tau antibody, E2814, at the Alzheimer’s Association International Conference.
